Amicus Therapeutics (GB:0HF9)

Amicus (0HF9) Share Price & Analysis


0HF9 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$7.55 - $13.73
Previous Close$11.03
Average Volume (3M)881.00
Market Cap
Enterprise Value$3.37B
Total Cash (Recent Filing)$267.11M
Total Debt (Recent Filing)$452.01M
Price to Earnings (P/E)N/A
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding284,575,686
10 Day Avg. Volume661
30 Day Avg. Volume881
Standard Deviation0.16
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)63.40
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.00
Enterprise Value/Gross Profit11.59
Enterprise Value/Ebitda-19.31
Price Target Upside33.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7




What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest share price was $7.55 and its highest was $13.72 in the past 12 months.
    What is Amicus Therapeutics’s market cap?
    Currently, no data Available
    When is Amicus Therapeutics’s upcoming earnings report date?
    Amicus Therapeutics’s upcoming earnings report date is Aug 03, 2023 which is in 64 days.
      How were Amicus Therapeutics’s earnings last quarter?
      Amicus Therapeutics released its earnings results on May 10, 2023. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.042.
        Is Amicus Therapeutics overvalued?
        According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Amicus Therapeutics pay dividends?
          Amicus Therapeutics does not currently pay dividends.
          What is Amicus Therapeutics’s EPS estimate?
          Amicus Therapeutics’s EPS estimate is -$0.12.
            How many shares outstanding does Amicus Therapeutics have?
            Currently, no data Available
            What happened to Amicus Therapeutics’s price movement after its last earnings report?
            Amicus Therapeutics reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -3.212%.
              Which hedge fund is a major shareholder of Amicus Therapeutics?
              Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 307M.


                Amicus Stock Smart Score

                The Amicus Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Amicus Therapeutics

                Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Abeona Therapeutics
                Akebia Therapeutics
                Akari Therapeutics
                Arrowhead Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis